Pacira BioSciences Sustainability Profile
Pacira BioSciences, Inc., a leading innovator in the biopharmaceutical industry, is headquartered in the United States. Founded in 2006, the company has made significant strides in advancing non-opioid pain management solutions, primarily through its flagship product, EXPAREL. This unique formulation of bupivacaine offers extended pain relief while minimising the reliance on opioids, addressing a critical need in postoperative care. With a strong presence across North America and expanding operations in international markets, Pacira BioSciences has established itself as a key player in the field of analgesia. The company’s commitment to improving patient outcomes and enhancing recovery experiences has garnered recognition, positioning it as a trusted name in pain management. Through continuous innovation and a focus on patient-centric solutions, Pacira BioSciences remains at the forefront of transforming the landscape of pain management therapies.
DitchCarbon Score
How does Pacira BioSciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pacira BioSciences's score of 25 is lower than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pacira BioSciences's reported carbon emissions
Pacira BioSciences, headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges from the company. This lack of data suggests that Pacira BioSciences may not have established formal commitments to reduce its carbon footprint or may be in the early stages of developing such initiatives. As the pharmaceutical industry increasingly focuses on sustainability, it is essential for companies like Pacira BioSciences to consider setting measurable climate targets and reporting their emissions to align with industry standards and stakeholder expectations. Without specific emissions data or reduction commitments, the company may face challenges in demonstrating its environmental responsibility and commitment to combating climate change.
How Carbon Intensive is Pacira BioSciences's Industry?
How Carbon Intensive is Pacira BioSciences's Location?
Pacira BioSciences's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Pacira BioSciences has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
